MNOVMediciNova, Inc.Healthcare · Biotechnologyas of 2026-09-16
Horizon

Issued 2026-09-16 at $2.52 · now $2.52 (2026-09-16, +0.0% since)

Based on its own history, a month from the 2026-09-16 close, MNOV has typically landed between $2.07 and $3.16 — a range of −18.0% to +25.4% from the issuance price $2.52.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.
  • Actual close
  • Typical path (median)
  • Middle 50% of outcomes
  • 90% range

4,951 overlapping 1 month windows · 2006-12-072026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.756.1%, ≈1,408 obs).

The cone is anchored at the 2026-09-16 issuance close ($2.52) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

Where MNOV has typically landed a month from the 2026-09-16 close of $2.52 — the range is history, not a prediction.

$2.07worst · -18.0%$3.16best · +25.4%
  • now $2.52 (+0.0%)
  • typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $2.44 (-3.1%)
  • middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $2.27$2.61
  • 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $2.07$3.16
Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 4,951 windows spanning 2006-12-07 to 2026-09-16. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.
StartReturnMax dropMax rise
3 worst
2011-03-07−58.4%−58.4%+0.0%
2011-03-04−55.3%−55.3%+3.2%
2011-03-08−55.0%−55.0%+0.0%
3 best
2009-06-19+174.8%+0.0%+174.8%
2009-06-24+151.2%+0.0%+177.8%
2009-06-22+150.0%−10.0%+150.0%

4,951 overlapping windows · 2006-12-072026-09-16 · not cherry-picked

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~20 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.
Jan
65%
+7.0%
n=20
Feb
45%
+5.3%
n=20
Mar
30%
−1.9%
n=20
Apr
50%
+2.9%
n=20
May
45%
−4.7%
n=20
Jun
50%
+1.3%
n=20
Jul
50%
+0.5%
n=20
Aug
55%
−0.0%
n=20
Sep
50%
+6.8%
n=20
Oct
53%
−1.1%
n=19
Nov
42%
−1.3%
n=19
Dec
21%
−8.6%
n=19

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Share price & reported tradesMonthly open-market valueReporting lag — trade date to filing date2026-092026-082026-072026-062026-052026-042026-032026-022026-012025-122025-112025-102025-092025-08$3$1↑ buys↓ sales
DatePersonRoleActionShares @ priceValueOwnership Δvs S&P 1mvs S&P 6mOwned afterFiling

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

13 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

DatePersonRoleActionSharesOwned afterFiling
2026-06-23BEAVER CAROLYNdirectorAward / grant44,50044,500Form 4
2026-06-23Lemerond NicoledirectorAward / grant44,50044,500Form 4
2026-06-23Nagao HidekidirectorAward / grant44,50044,500Form 4
2026-01-16IWAKI YUICHIdirectorAward / grant450,000450,000Form 4
2026-01-16Matsuda KazukodirectorAward / grant350,000350,000Form 4
2025-06-17BEAVER CAROLYNdirectorAward / grant20,00020,000Form 4
2025-02-12Nagao HidekidirectorAward / grant24,50024,500Form 4
2025-02-12BEAVER CAROLYNdirectorAward / grant24,50024,500Form 4
2025-02-12IWAKI YUICHIdirectorAward / grant100,000100,000Form 4
2025-02-12Lemerond NicoledirectorAward / grant24,50024,500Form 4
2025-02-12Matsuda KazukodirectorAward / grant100,000100,000Form 4
2025-01-07IWAKI YUICHIdirectorAward / grant400,000400,000Form 4
2025-01-07Matsuda KazukodirectorAward / grant300,000300,000Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.